

# Sarcoma Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart



## First Line

## Second Line

**UCI 25-231**  
AIM vs No chemo + Sx  
Coord: B. TBD  
Accrual: 0/5

**UCI 24-08**  
SPEDOX -6 (Protein encapsulated doxorubicin)  
Coord: E. Palmer-Torrison  
Accrual: 5/50

## Recurrent/Metastatic

UCI 24-175

Ziftomenib, Imatinib

Coord: B. Huynh

Accrual: 0/5

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended



## Supportive Care

### UCI 24-05

Riluzole PO vs. Placebo PO  
Perceived worsening of *cognitive function*

**\*BREAST COHORT FULL\***

PI: Chan

CRC: Randy Kang

Accrual: 24/39

### UCI 25-48

Riluzole PO vs. Placebo PO  
Pts starting anthracycline/platinum agent

PI: Chan

CRC: Madeleine Phan

Accrual: 2/20

